With the House and Senate heading into a monthlong August recess this week, it’s a good time to look back at what lawmakers have accomplished so far in 2019 when it comes to marijuana reform: It is unquestionable that the 116th Congress is the most cannabis-friendly Congress in history.

Seven months into the session, there already have been seven hearings on cannabis, a marijuana banking bill passed a key committee, and the full House adopted a far-reaching amendment to block federal interference in state legalization laws. And those are just the highlights.

“Congress has never moved this far, this fast on marijuana policy, period,” Justin Strekal, the National Organization for the Reform of Marijuana Laws (NORML) Political Director, said in an interview. 

Democratic Rep. Earl Blumenauer of Oregon, who has worked for decades to end marijuana prohibition, said that those “long overdue efforts to reform our outdated cannabis laws are finally resonating in Congress.”

“Bills to address policy failures in cannabis banking, veterans access, decriminalization and restorative justice have started moving through the legislative process,” he said.

Here’s a comprehensive rundown of the immense amount of cannabis progress made on Capitol Hill in 2019:

Votes on Marijuana Legislation

In June, the House of Representatives voted 267-165 to approve a measure for the first time that prevents the Department of Justice from spending money to intervene in the implementation of state and territory marijuana policies.

The body also approved, via an uncontested voice vote, a similar measure shielding the cannabis laws of Indian tribes as well as another adding the U.S. Virgin Islands to an existing law covering local medical marijuana programs. An additional amendment the House tacked onto the same bill directs the Food and Drug Administration (FDA) to establish a process for regulating CBD in foods and dietary supplements.

Separate appropriations legislation that cleared the House in June contained language upon introduction to prohibit the Treasury Department from punishing banks for maintaining accounts for state-legal cannabis businesses. That legislation also deletes a longstanding rider that has blocked Washington, D.C., from spending its own local tax dollars to legalize and regulate marijuana sales. No lawmaker from either party attempted to completely strip the banking language or add the D.C. ban back in.

The Senate has not yet taken up its versions of these spending bills, so it remains to be seen if the chamber will support similar amendments during committee markups or floor consideration. In cases where the body does not adopt identical proposals, it will be up to bicameral conference committees to determine what makes it into final legislation sent to President Donald Trump’s desk.

In July, the House passed via voice vote an amendment to end a Department of Veterans Affairs (VA) policy that denies home loans to military veterans because they work in the marijuana industry. The underlying bill, the National Defense Authorization Act (NDAA), also contains a separate measure added in committee that would let military branches grant reenlistment waivers to personnel if they used marijuana once, or were convicted of a misdemeanor cannabis offense, while off duty. The Senate version of NDAA doesn’t have these marijuana riders, so it will come down to a conference committee to decide if they are included in the finished package.

In March, the House Financial Services Committee voted 45-15 to approve a bill to let banks service marijuana businesses without being punished by federal regulators.

Much of the progress on cannabis legislation so far this year is due to the fact that Democrats won control of the House and thereby replaced the former Republican Rules Committee Chair Rep. Pete Sessions of Texas — who lost his own re-election bid — with new Chair, Democratic Rep. James McGovern of Massachusetts. The panel is responsible for preparing legislation for floor action and, among other things, decides which amendments are allowed to be voted on by the full body. Under Sessions’ control, the GOP majority blocked every proposed cannabis measure from advancing for the past several years. McGovern has allowed nearly all marijuana amendments to be considered on the floor, with the exception of one that had technical issues in violation of House rules.

It is worth noting that it hasn’t been all legislative victories for drug reform activists this year on Capitol Hill. A measure that Democratic Rep. Alexandria Ocasio-Cortez of New York filed to remove roadblocks to research on the medical benefits of psilocybin (magic mushrooms), MDMA (ecstasy), and other psychedelics was soundly defeated on the House floor, with a number of Democratic leaders joining the GOP in voting against it. And Blumenauer withdrew his own amendment to let VA doctors issue medical cannabis recommendations after the administration pushed back against it. Planned committee votes on other veterans-focused marijuana legislation were canceled and haven’t yet been rescheduled.

And while supporters had anticipated a House floor vote on the cannabis banking bill prior to the August recess, that did not happen, and expectations have now shifted toward action in the fall.

Hearings on Cannabis Issues

An unprecedented number of hearings have already been held on Capitol Hill this year to zero in on specific issues caused by the growing gap between federal and state cannabis laws.

The Senate Banking, Housing, and Urban Affairs Committee held a hearing on financial services access for marijuana businesses on July 23 — a surprise to advocates following the earlier refusal of Republican Chairman Sen. Mike Crapo of Idaho to commit to considering the issue while cannabis remains federally banned. While the event was poorly attended by panel Republicans, it at least signals the GOP-controlled body’s willingness to discuss key reforms. It is unknown if or when the committee will vote on pending marijuana banking legislation that is currently co-sponsored by nearly a third of all senators.

The Senate Agriculture Committee convened a July 25 hearing on federal officials’ efforts to implement the legalization of hemp that was part of the 2018 Farm Bill signed into law by Trump in late 2018. Among those who testified were representatives from the U.S. Department of Agriculture (USDA), the FDA, and the Environmental Protection Agency (EPA).

On the House side, the Judiciary Subcommittee on Crime, Terrorism, and Homeland Security gathered on July 10 for a hearing on the need to end cannabis prohibition at which every witness — including the one called by the panel’s minority Republicans — supported far-reaching federal marijuana reform. Lawmakers from both parties also broadly voiced support for ending or scaling back prohibition, with most disagreement centering on how to achieve change instead of whether changes are needed.

The House Veterans’ Affairs Committee held two hearings, during which legislators discussed proposals to increase military veterans’ access to medical cannabis. During a full panel session in June as well as a separate earlier meeting of the Subcommittee on Health, a key focus was on bipartisan proposals to force the VA to at least study medical marijuana.

Also in June, the House Small Business Committee discussed challenges facing firms in the cannabis industry, including a lack of access to federally backed low-interest loans.

In February, the House Financial Services Consumer Protection and Financial Institutions Subcommittee convened to discuss banking access issues for marijuana businesses, a hearing that preceded full committee passage of legislation on the issue.

Marijuana Bills From Key Sponsors

No fewer than 61 individual cannabis-focused bills have been filed in the first seven months of the 116th Congress, and that doesn’t count a number of broader large-scale bills that happen to contain cannabis provisions. Beyond the sheer volume of legislation—already nearly the most in any single two-year Congress despite the fact that barely a quarter of the current one has so far elapsed — the names of the lead sponsors signal how seriously cannabis reform is now being taken on Capitol Hill.

Including committee chairs and presidential candidates, many of the most serious players in the House and Senate are stepping up to play leadership roles in the fight to reform federal marijuana laws.

Democrats Rep. Jerrold Nadler of New York, who strongly influences crime and drug policy as House Judiciary Committee chair, and Sen. Kamala Harris of California, a presidential contender, teamed up to file companion bills that would not only federally legalize marijuana but also invest in programs aimed at repairing some of the damage of the war on drugs.

Democratic House Small Business Committee Chair Rep. Nydia Velazquez of New York introduced legislation to let marijuana firms utilize loans and other programs from the Small Business Administration and to increase the cannabis industry’s access to insurance coverage.

New Yorkers Democratic Senate Minority Leader Chuck Schumer and House Democratic Caucus Chairman Rep. Hakeem Jeffries filed bills to deschedule cannabis and set aside funding to support expunging prior convictions.

Every Democratic senator and representative currently running for their party’s 2020 presidential nomination has signed onto far-reaching cannabis legislation, with some taking extra initiative as the lead sponsors of bills.

Sen. Cory Booker of New Jersey, for example, filed a proposal called the Marijuana Justice Act, which would remove cannabis from the Federal Controlled Substances Act (CSA) and punish states with discriminatory prohibition enforcement by withholding certain federal funds. Sen. Elizabeth Warren of Massachusetts is a lead sponsor of bipartisan legislation to exempt state-legal marijuana activity from the CSA. Rep. Tulsi Gabbard of Hawaii filed bills to deschedule marijuana and to research hemp’s potential uses for everything from products for public school lunches to clearing contaminants from nuclear sites.

Sens. Michael Bennet of Colorado, Kirsten Gillibrand of New York, Amy Klobuchar of Minnesota, as well as Reps. Seth Moulton of Massachusetts and Tim Ryan of Ohio — all presidential candidates, along with nomination-seeker independent Bernie Sanders of Vermont — have signed onto cannabis reform proposals.

While Democrats have been much more likely to introduce or cosponsor marijuana reform bills so far this Congress, some measures have garnered significant bipartisan support.

Legislation to let banks serve cannabis businesses without fear of being punished by federal regulators, for example, has 206 House co-sponsors — nearly half of the chamber’s entire membership — including 26 Republicans. A companion Senate bill has 31 lawmakers signed on, including five GOP senators. And Warren’s bill, known as the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, also has five Republican co-sponsors, with the companion House version touting 19 GOP signers.

Report Language on Cannabis

Beyond advancing legislation containing marijuana reform provisions, the House Appropriations Committee has included language directing federal agencies to take action on cannabis issues in several reports attached to spending bills this year.

In a document corresponding to legislation to fund the departments of Labor, Health and Human Services, and Education, the panel expressed concern that cannabis’s current federal classification impedes science, writing that “restrictions associated with Schedule I of the Controlled Substances Act effectively limit the amount and type of research that can be conducted on certain Schedule I drugs, especially marijuana or its component chemicals and new synthetic drugs and analogs.

“At a time when we need as much information as possible about these drugs to find antidotes for their harmful effects, we should be lowering regulatory and other barriers to conducting this research,” the panel said, directing the National Institute on Drug Abuse to “provide a short report on the barriers to research that result from the classification of drugs and compounds as Schedule I substances.”

A separate report for legislation funding the Department of Justice (DOJ) urges the Drug Enforcement Administration (DEA) to “expeditiously process any pending applications for authorization to produce marijuana exclusively for use in medical research,” expressing frustration that the federal government has so far not acted on more than two dozen pending proposals to grow cannabis for scientific studies.

A document attached to the Financial Services and General Government spending bill encourages the Office of Personnel Management (OPM) to “review its policies and guidelines regarding hiring and firing of individuals who use marijuana in states where that individual’s private use of marijuana is not prohibited under the law of the State.”

“These policies should reflect updated changes to the law on marijuana usage and clearly state the impact of marijuana usage on Federal employment,” the report says.

Legislation on Agriculture, Rural Development and FDA funding has an attached report urging federal officials to issue hemp legalization regulations “as soon as possible” and identify “lawful federal regulatory pathways for CBD foods and dietary supplements if such pathways are consistent with protection of the public health.”

The committee also included a passage in the report attached to a bill funding the VA decrying the “Department’s denial of home loan guarantees to Veterans solely on the basis of the Veteran’s documented income being derived from state-legalized cannabis activities” and directing it to provide an update on efforts to “prioritize investments in research on the efficacy and safety of cannabis usage among the Veteran population for medicinal purposes.”

Looking Ahead

There’s still nearly a year and a half left to go in the 116th Congress, and legalization advocates are hopeful that far-reaching reforms can pass one or both chambers, potentially making it to President Trump’s desk to be signed into law.

Michael Collins, director of national affairs for the Drug Policy Alliance (DPA), said that things are “off to a great start in the House,” calling the Judiciary Committee hearing and the introduction of its chairman’s bill “highlights” so far.

“But there is so much more to be done before we can celebrate undoing the horror that is marijuana prohibition,” he added.

Most immediately, activists will be watching to see if the House moves to pass cannabis banking legislation and potentially Judiciary Chair Nadler’s comprehensive marijuana reform bill when Congress returns from the August recess.

Blumenauer, the pro-legalization congressman, said that he hopes the body will consider Nadler’s descheduling legislation “before the end of the year.”

“This is our blueprint in action, and I expect our momentum to continue,” he said, referring to a memo he issued to Democratic leaders last year laying out a committee-by-committee process through which the party could build support toward ending cannabis prohibition in 2019.

On the other side of the Capitol, it remains to be seen whether the Senate Banking Committee will take up that chamber’s version of the cannabis financial services proposal following the hearing the panel held in July, or whether broader reforms such as the STATES Act or other marijuana legislation will be allowed to advance under Republican Majority Leader Mitch McConnell of Kentucky.

While bill introductions, hearings and report language are undoubtedly positive steps forward — especially in a quantity never before seen on Capitol Hill — they in and of themselves don’t change any laws, get anyone out of jail or repair the harms of the drug war.

Strekal, of NORML, said that “lawmakers are increasingly playing catch up with their constituents.”

“It’s our job as advocates to ensure that, as these elected officials evolve, they navigate their positions towards sound public policy, not simple political expediency,” he said.

But even if no other marijuana action were to happen on Capitol Hill in 2019 or 2020 — as unlikely as that would be — it is clear that the 116th Congress has already been the most marijuana-friendly in American history.


Feature image: The 116th Congress, encompassing the 2019 and 2020 sessions, has seen hearings and potential legislation to make cannabis more accessible at a rate unmatched by any other Congress, according to Marijuana Moment’s analysis.  (Gina Coleman/Weedmaps)

This article was republished from Marijuana Moment under a content syndication agreement. Read the original article here

Powered by WPeMatico